Showing results (131-140 of 138) with videos related to

Sort By:
Pageof 14
You have reached the last page of results.This site can display upto 138 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 20, 2014
A multicenter DeCOG study on predictors of vemurafenib therapy outcome in melanoma: pretreatment impacts survivalS Ugurel, C Loquai, K Kähler, et al.
European Journal of Cancer (Oxford, England : 1990)|December 12, 2025
Characteristics and quality of life of nine-year survivors with metastatic melanoma treated with pembrolizumab beyond second-line therapyS Dugas-Breit, A Forschner, M Erdmann, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 8, 2014
Differential influence of vemurafenib and dabrafenib on patients' lymphocytes despite similar clinical efficacy in melanomaB Schilling, W Sondermann, F Zhao, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 13, 2015
Radiosensitization by BRAF inhibitor therapy-mechanism and frequency of toxicity in melanoma patientsM Hecht, L Zimmer, C Loquai, et al.
The British Journal of Dermatology|February 13, 2018
A randomized, multinational, noninferiority, phase III trial to evaluate the safety and efficacy of BF-200 aminolaevulinic acid gel vs. methyl aminolaevulinate cream in the treatment of nonaggressive basal cell carcinoma with photodynamic therapyC A Morton, R Dominicus, P Radny, et al.
European Journal of Cancer (Oxford, England : 1990)|February 6, 2019
Sequence-dependent cross-resistance of combined radiotherapy plus BRAFV600E inhibition in melanomaB Shannan, J Matschke, H Chauvistré, et al.
The British Journal of Dermatology|September 14, 2011
Photodynamic therapy with BF-200 ALA for the treatment of actinic keratosis: results of a multicentre, randomized, observer-blind phase III study in comparison with a registered methyl-5-aminolaevulinate cream and placeboT Dirschka, P Radny, R Dominicus, et al.
The British Journal of Dermatology|December 21, 2012
Long-term (6 and 12 months) follow-up of two prospective, randomized, controlled phase III trials of photodynamic therapy with BF-200 ALA and methyl aminolaevulinate for the treatment of actinic keratosisT Dirschka, P Radny, R Dominicus, et al.
Pageof 14